NASDAQ:FOLD - Amicus Therapeutics Stock Price, Forecast & News

Amicus Therapeutics trades on the NASDAQ under the ticker symbol "FOLD."

Amicus Therapeutics, Inc. (NASDAQ:FOLD) posted its quarterly earnings data on Monday, November, 11th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.32) by $0.08. The biopharmaceutical company earned $48.80 million during the quarter, compared to the consensus estimate of $48.05 million. Amicus Therapeutics had a negative return on equity of 62.61% and a negative net margin of 216.02%. Amicus Therapeutics's quarterly revenue was up 136.9% on a year-over-year basis. During the same period last year, the company earned ($0.84) earnings per share. View Amicus Therapeutics' Earnings History.

Amicus Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, March 2nd 2020. View Earnings Estimates for Amicus Therapeutics.

Amicus Therapeutics will be holding an earnings conference call on Monday, March 2nd at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Amicus Therapeutics updated its FY 2019 Pre-Market earnings guidance on Tuesday, February, 4th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $181-181 million, compared to the consensus revenue estimate of $179.1 million.

5 brokers have issued 12 month price targets for Amicus Therapeutics' stock. Their forecasts range from $13.91 to $31.00. On average, they anticipate Amicus Therapeutics' stock price to reach $20.98 in the next twelve months. This suggests a possible upside of 114.6% from the stock's current price. View Analyst Price Targets for Amicus Therapeutics.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amicus Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Amicus Therapeutics.

Headlines about FOLD stock have trended negative recently, InfoTrie Sentiment reports. The research group identifies positive and negative press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Amicus Therapeutics earned a daily sentiment score of -2.0 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Amicus Therapeutics.

Amicus Therapeutics saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 35,950,000 shares, an increase of 8.1% from the January 15th total of 33,260,000 shares. Based on an average daily volume of 3,120,000 shares, the days-to-cover ratio is presently 11.5 days. Approximately 14.5% of the shares of the stock are short sold. View Amicus Therapeutics' Current Options Chain.

Some companies that are related to Amicus Therapeutics include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Amicus Therapeutics investors own include NVIDIA (NVDA), AcelRx Pharmaceuticals (ACRX), Sangamo Therapeutics (SGMO), Sarepta Therapeutics (SRPT), Cara Therapeutics (CARA), Exelixis (EXEL), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Synergy Pharmaceuticals (SGYP) and Novavax (NVAX).

Amicus Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include Perceptive Advisors LLC (9.86%), Perceptive Advisors LLC (9.86%), State Street Corp (4.32%), Janus Henderson Group PLC (4.22%), Palo Alto Investors LP (2.91%) and Jennison Associates LLC (2.83%). Company insiders that own Amicus Therapeutics stock include Bradley L Campbell, Burke W Whitman, Daphne Quimi, Ellen Rosenberg, Hung Do, Jay Barth, John F Crowley, Kurt J Andrews, Life Sciences Maste Perceptive, Margaret G Mcglynn, Michael Raab, Perceptive Advisors Llc and William D Baird III. View Institutional Ownership Trends for Amicus Therapeutics.

FOLD stock was sold by a variety of institutional investors in the last quarter, including Bank of America Corp DE, Sectoral Asset Management Inc, Franklin Resources Inc., Renaissance Technologies LLC, FMR LLC, State Street Corp, UBS Group AG and Spark Investment Management LLC. Company insiders that have sold Amicus Therapeutics company stock in the last year include Bradley L Campbell, Daphne Quimi, Ellen Rosenberg, Jay Barth, John F Crowley, Margaret G Mcglynn and Michael Raab. View Insider Buying and Selling for Amicus Therapeutics.

FOLD stock was bought by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Goldman Sachs Group Inc., Rothschild & Co. Asset Management US Inc., Perceptive Advisors LLC, Perceptive Advisors LLC, Barclays PLC, Assenagon Asset Management S.A. and Panagora Asset Management Inc.. Company insiders that have bought Amicus Therapeutics stock in the last two years include Burke W Whitman, Life Sciences Maste Perceptive and Perceptive Advisors Llc. View Insider Buying and Selling for Amicus Therapeutics.

Shares of FOLD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of FOLD stock can currently be purchased for approximately $9.78.

Amicus Therapeutics has a market capitalization of $2.49 billion and generates $91.25 million in revenue each year. The biopharmaceutical company earns $-348,990,000.00 in net income (profit) each year or ($1.33) on an earnings per share basis. Amicus Therapeutics employs 508 workers across the globe.View Additional Information About Amicus Therapeutics.

The official website for Amicus Therapeutics is http://www.amicusrx.com/.

Amicus Therapeutics' mailing address is 1 Cedar Brook Drive, Cranbury NJ, 08512. The biopharmaceutical company can be reached via phone at 609-662-2000 or via email at [email protected]